Engagement of immune effector cells by trastuzumab induces HER2/ERBB2 downregulation in cancer cells through STAT1 activation

INTRODUCTION: Trastuzumab has been widely used for the treatment of human epidermal growth factor receptor 2 (HER2) overexpressing breast cancer for more than a decade. However, reports on the involvement of HER2 downregulation in trastuzumab’s mechanism of action are inconsistent. The aim of this s...

Descripción completa

Detalles Bibliográficos
Autores principales: Shi, Yun, Fan, Xuejun, Meng, Weixu, Deng, Hui, Zhang, Ningyan, An, Zhiqiang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2014
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4053225/
https://www.ncbi.nlm.nih.gov/pubmed/24693969
http://dx.doi.org/10.1186/bcr3637

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4053225/
https://www.ncbi.nlm.nih.gov/pubmed/24693969
http://dx.doi.org/10.1186/bcr3637

Ejemplares similares